Spinal Elements IPO Set to Turn Necks

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Spinal Elements IPO Set to Turn Necks

© Sam Edwards / Getty Images

Spinal Elements Holdings has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company intends to price its 7.7 million shares in the range of $13 to $15 apiece, with an overallotment option for an additional 1.155 million shares. At the maximum price, the entire offering is valued up to $132.8 million. The company intends to list its shares on the Nasdaq under the symbol SPEL.

[in-text-ad]

The underwriters for the offering are Baird, BTIG, Credit Suisse, Siebert Williams Shank, Stifel and Truist.

This medical device company is focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery procedures.

[nativounit]

Its product portfolio addresses a broad spectrum of spine surgery procedures. It consists of the following:

  • Innovative spinal fixation systems (implantable hardware systems that are mechanically attached to the spine and provide stability)
  • Interbody implants (devices implanted between the vertebral bodies of the spine)
  • Surgical instruments (instruments used to prepare the spine and implant our devices)
  • And biologics (allograft or synthetic biomaterials intended to augment or replace the normal capacity of such tissue in the body)

The company’s product portfolio can address roughly 95% of the spine surgery procedures performed worldwide in 2018, and these systems, products and technologies cover a wide variety of spine disorders, including degenerative conditions, deformities and trauma.

Looking ahead, Spinal Elements expects to continue to complement its existing product portfolio with new product offerings based on innovative technologies. Management believes its comprehensive product portfolio has the potential to enhance the way surgeons operate and to disrupt the spine surgery market.

The company intends to use the net proceeds from this offering to repay its indebtedness, as well as for working capital and general corporate purposes.

[recirclink id=800602][wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618